Heptares Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Heptares Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10867
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heptares Therapeutics Ltd (Heptares) a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise StaR technology, StaR-driven X-ray crystallography, Biophysical Mapping and StaR fragment screening. Heptares’ products are used in the treatment of Alzheimer’s disease, schizophrenia, binge eating, type 2 diabetes, autism, depression, dyskinesia, migraine treatment, and others. The company partners with other pharma and biotech companies to develop its products. Heptares is headquartered in Welwyn Garden, the UK.

Heptares Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Partnerships 13
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Licensing Agreements 28
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Acquisition 31
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd – Key Competitors 33
Heptares Therapeutics Ltd – Key Employees 34
Heptares Therapeutics Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Jan 04, 2018: Heptares Scientists Solve Structure of Complement C5a Receptor, an Important Drug Target for Inflammatory and Neurodegenerative Diseases, and Cancer 36
May 31, 2017: Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 37
Product News 38
May 31, 2017: Sosei Subsidiary Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist 38
05/18/2017: Heptares to Receive US$5 Million Milestone Payment from Teva 39
Clinical Trials 40
Apr 05, 2017: Heptares to Receive US$12 Million Milestone Payment from Astrazeneca 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heptares Therapeutics Raises US$21 Million In Series B Financing 12
Heptares Therapeutics Enters into Co-Development Agreement with DyNAbind 13
Heptares Therapeutics Enters into Research Agreement with Imperial College London 14
Heptares Therapeutics Enters into Research Agreement with Juntendo University 15
Heptares Therapeutics and PeptiDream Enter into Agreement 16
Heptares Therapeutics Enters into Research Agreement with New York University School of Medicine 17
Heptares Therapeutics Enters into Research Agreement with University of Cambridge 18
Jitsubo Enters into Agreement with Heptares Therapeutics 19
Heptares Therapeutics and leadXpro Enter into Agreement 20
Heptares Therapeutics to Form Partnership with Kymab 21
Heptares Therapeutics Enters into Agreement with Pfizer 22
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 23
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 24
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 25
Heptares Therapeutics Extends Collaboration with the UK Medical Research 26
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 27
Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 28
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 29
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 30
Heptares Therapeutics Acquires G7 Therapeutics for USD11.8 Million 31
Sosei Acquires Heptares Therapeutics for USD400 Million 32
Heptares Therapeutics Ltd, Key Competitors 33
Heptares Therapeutics Ltd, Key Employees 34
Heptares Therapeutics Ltd, Subsidiaries 35

List of Figures
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heptares Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Heptares Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tana Exploration Company LLC:企業のM&A・提携動向(石油・ガス分野)
    Summary Tana Exploration Company LLC (Tana Exploration) is an oil and gas exploration company that develops oil and gas resources. The company offers products such as crude oil and natural gas. It provides services such as technical support, financial support and remodeling. Tana Exploration’s provi …
  • University of California Los Angeles:医療機器:M&Aディール及び事業提携情報
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California, is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, gradua …
  • Excelsior Medical Co Ltd (4104)-医療機器分野:企業M&A・提携分析
    Summary Excelsior Medical Co., Ltd. (Excelsior Medical), formerly Enfield Medical Co., Ltd. is a medical equipment manufacturer that develops and markets products for intraluminal catheter care. The company’s products include SwabCap, SwabFlush, SwabKIT, ZR syringes, flush syringes, PharmAssist and …
  • FCA US LLC (formerly Chrysler Group LLC):企業の戦略・SWOT・財務分析
    SummaryFCA US LLC (formerly Chrysler Group LLC) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of …
  • Dedeman Hotels and Resorts International:企業概要及びSWOT分析
    Summary Canadean's "Dedeman Hotels and Resorts International: Travel and Tourism - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business …
  • Kirin Holdings Co Ltd:戦略・SWOT・企業財務分析
    Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Barclays Plc:企業のM&A・事業提携・投資動向
    Barclays Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barclays Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Xcite Energy Limited (XEL)-石油・ガス分野:企業M&A・提携分析
    Summary Xcite Energy Limited (Xcite Energy) is a heavy oil appraisal and development company. It focuses on the development of discovered oil resources in the UK North Sea. Xcite Energy has 100% working interest in the Bentley field in the UK North Sea. It also holds and operates three other blocks …
  • Becker Avionics, Inc.:企業の戦略・SWOT・財務分析
    SummaryBecker Avionics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key F …
  • Northern Oil & Gas, Inc. (NOG):企業財務及び戦略的SWOT分析
    Summary Northern Oil & Gas, Inc. (Northern) is an oil and gas company that offers exploration services. The company acquires and maintains properties in Bakken and Three Forks formations within the Williston Basin. It offers services such exploration and production through its non-operating working …
  • Opexa Therapeutics Inc (OPXA):企業財務及び戦略的SWOT分析
    Summary Opexa Therapeutics Inc (Opexa), formerly PharmaFrontiers Corp. is a biopharmaceutical company that focuses on the development of personalized immunotherapies for autoimmune disorders, rheumatoid arthritis, diabetes and heart failure. The company’s portfolio of products comprise Tcelna, a T-c …
  • Forrester Research, Inc. (FORR):企業の財務及び戦略的SWOT分析
    Summary Forrester Research, Inc. (Forrester) is a research service provider that offers various advisory services. The company offers services such as custom consulting, proprietary research, consumer and business data, worldwide events, and peer executive programs. It provides research for professi …
  • Power Integrations, Inc. (POWI):企業の財務及び戦略的SWOT分析
    Summary Power Integrations, Inc. (Power Integrations) is an electric equipment company that supplies electronic components used in high-voltage power-conversion systems. The company’s products include chiphy, LYTswitch, linkzero, linkswitch, potswitch, hiper, capzero, senzero, dpa-switch and qspeed. …
  • Citizens Financial Corp.:企業の戦略・SWOT・財務情報
    Citizens Financial Corp. - Strategy, SWOT and Corporate Finance Report Summary Citizens Financial Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kratos Defense and Security Solutions, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Kratos Defense and Security Sol …
  • Aveda Transportation and Energy Services Inc. (AVE):企業財務及び戦略的SWOT分析
    Summary Aveda Transportation and Energy Services Inc. (Aveda), formerly Phoenix Oilfield Hauling Inc. is an oil field service provider that provides transportation services and other energy related services. The company offers specialized transportation services and equipment for drilling, explorati …
  • Galadari Hotels (Lanka) PLC :企業の戦略・SWOT・財務情報
    Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report Summary Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Timeless Software Limited (8028):企業の財務及び戦略的SWOT分析
    Summary Timeless Software Limited (Timeless Software) is a technology service provider that offers services such as web services, software development, total solutions of latest technology, cloud services and TFolder, and web designing. The company’s projects include knowledge management, ecommerce, …
  • M.J. Maillis S.A. Industrial Packaging Systems and Technologies:企業の戦略・SWOT・財務分析
    SummaryM.J. Maillis S.A. Industrial Packaging Systems and Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, p …
  • Eagle Materials Inc (EXP):企業の財務・戦略的SWOT分析
    Eagle Materials Inc (EXP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆